Alan Fixelle, MD
Gastroenterology · Atlanta, GANPI 1851319164
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,867 of the $2,541 with a category attached, or 73.5%. 19 manufacturers reported payments, led by AbbVie at 39.7% of the total. That places this record below the midpoint for gastroenterology clinicians in GA, where the typical reported total is $3,789.
Across 105 payments — averaging $24.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Olympus America Inc.$539
- Johnson & Johnson$446
- Regeneron Healthcare Solutions, Inc.$90
- Sanofi$79
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$74
- plus $304 from 13 others
Across 2 payments — averaging $9400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$19K
What the payments were for
- Food & beverage$1,86773%
- Education$1355%
- Other$53921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $1,009 |
| Olympus America Inc. | 1 | $539 |
| Johnson & Johnson(2 entities) | 22 | $446 |
| Regeneron Healthcare Solutions, Inc. | 4 | $90 |
| Sanofi | 3 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $74 |
| Janssen Scientific Affairs, LLC | 2 | $74 |
| Ferring Pharmaceuticals Inc. | 3 | $42 |
| Boston Scientific | 2 | $33 |
| Pfizer | 2 | $26 |
| Mauna Kea Technologies, Inc. | 1 | $23 |
| UCB, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $12 |
| Braintree Laboratories, Inc. | 1 | $12 |
| Intercept Pharmaceuticals, Inc. | 1 | $11 |
| Romark Laboratories, LC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humira$125
How this compares
$2,541 in reported general payments places this provider in the 40th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cimzia (2 Pack)Certolizumab Pegol | 17 | $112,793 |
| Humira PenAdalimumab | 14 | $99,824 |
| Humira(Cf) PenAdalimumab | 14 | $97,713 |
| Entyvio PenVedolizumab | 12 | $77,054 |
| CreonLipase/Protease/Amylase | 31 | $52,785 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 188 | $32,341 |
| LinzessLinaclotide | 23 | $29,385 |
| ZenpepLipase/Protease/Amylase | 11 | $26,620 |
| Mesalamine | 57 | $12,090 |
| Dexlansoprazole DrDexlansoprazole | 22 | $10,138 |
| Alosetron Hcl | 12 | $7,178 |
| Colesevelam Hcl | 15 | $5,613 |
| Pantoprazole Sodium | 331 | $4,266 |
| Lubiprostone | 11 | $3,358 |
| Esomeprazole Magnesium | 58 | $2,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Cimzia (2 Pack) | $18 | $112,79317 claims |
| AbbVieCreon, Linzess | $1,009 | $82,17054 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $42 | $32,341188 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Atlanta
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Roshan ShresthaAtlanta$317K
- Hetal KarsanAtlanta$314K
- Marc SonenshineAtlanta$201K
- Julia LiuAtlanta$163K
- Huiming HonAtlanta$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.